Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Pharmaceutical Sales — Japan: $558M in Q2 2026, down 7.6% from a year earlier.
Latest, Q2 2026
558
Period ended Jun 30, 2026
Change on a year earlier
-7.6%
604 in Q2 2025
History
40 quarters
Since Q1 2016
Sources
16
Documents cited below
Where the Q2 2026 figure comes from
“|| Japan | 535 | 558 | 1,093 | 651 | 604 | 1,255 | 693 | 684 | 2,632 | -8 | -13”
Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Reported in Form 8-K Supplemental Table 3c / 3b (Pharmaceutical Geographic Sales).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up pharmaceutical Sales — Japan
Cite this data
StockData. (2026). Merck Pharmaceutical Sales — Japan ($M), quarterly Q1 2016–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/pharma-geo-japan
See every metric in the Merck KPI table. Data updated Oct 26, 2026.